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Abstract
The outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical
removal of the primary tumor focusing on their histopathological characteristics. Tumor staging (AJCC/UICC-TNM
classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes
(N), and evidence for metastases (M). However, this classification provides limited prognostic information in
estimating the outcome in cancer and does not predict response to therapy. It is recognized that cancer outcomes
can vary significantly among patients within the same stage. Recently, many reports suggest that cancer
development is controlled by the host’s immune system underlying the importance of including immunological
biomarkers for the prediction of prognosis and response to therapy. Data collected from large cohorts of human
cancers demonstrated that the immune-classification has a prognostic value that may be superior to the AJCC/
UICC TNM-classification. Thus, it is imperative to begin incorporating immune scoring as a prognostic factor and to
introduce this parameter as a marker to classify cancers, as part of the routine diagnostic and prognostic
assessment of tumors. At the same time, the inherent complexity of quantitative immunohistochemistry, in
conjunction with variable assay protocols across laboratories, the different immune cell types analyzed, different
region selection criteria, and variable ways to quantify immune infiltration underscore the urgent need to reach
assay harmonization. In an effort to promote the immunoscore in routine clinical settings worldwide, the Society
for Immunotherapy of Cancer (SITC), the European Academy of Tumor Immunology, the Cancer and Inflammation
Program, the National Cancer Institute, National Institutes of Health, USA and “La Fondazione Melanoma” will jointly
initiate a task force on Immunoscoring as a New Possible Approach for the Classification of Cancer that will take
place in Naples, Italy, February 13
th, 2012. The expected outcome will include a concept manuscript that will be
distributed to all interested participants for their contribution before publication outlining the goal and strategy to
achieve this effort; a preliminary summary to be presented during the “Workshop on Tumor Microenvironment”
prior to the SITC annual meeting on October 24
th -2 5
th 2012 in Bethesda, Maryland, USA and finally a “Workshop
on Immune Scoring” to be held in Naples in December of 2012 leading to the preparation of a summary
document providing recommendations for the harmonization and implementation of the Immune Score as a new
component for the classification of cancer.
Introduction
Conventional clinical and pathological risk prediction in
cancer patients is usually achieved by evaluating tissue
samples obtained during surgical removal of the primary
tumor, mostly focusing on their histopathological char-
acteristics. These can include the size of the tumor
within the tissue, atypical cell morphology, tissue
integrity, aberrant expression of protein and recently
genetic markers or other evidence of malignant transfor-
mation, senescence and proliferation, various character-
istics of the invasive margin, depth of invasion, and the
extent of vascularization. In addition, histological or
radiological analysis of both, tumor draining- and regio-
nal lymph nodes, as well as of distant organs are carried
out looking to identify evidence of metastases. In accor-
dance with these staging data, the evaluation of cancer
progression is performed longitudinally and is further
applied to estimate the patient prognosis. Available
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any medium, provided the original work is properly cited.statistical data of patients with similar progression char-
acteristics and their actual outcome parameters such as
average disease-free (DFS), disease-specific (DSS) and
overall survival (OS) are used for the estimation. Tumor
staging (AJCC/UICC-TNM classification) summarizes
data on tumor burden (T), presence of cancer cells in
draining and regional lymph nodes (N) and evidence for
metastases (M). Until now, this classification which is
only based on tumor invasion parameters has been
shown to be valuable in estimating the outcome of
patients with a variety of cancers [1-3].
Still, it is well known that it provides limited informa-
tion for prognosis since cancer outcome can signifi-
cantly vary among patients within the same histological
tumor stage. In some patients, advanced stage cancer
can remain stable for years, and partial or full regression
of metastatic tumors can occur spontaneously [4],
although this is rare. On the other hand, rapid progres-
sion and death of patients with early cancers is often
seen, even after complete surgical removal of the macro-
scopically visible tumor, and with no evidence of resi-
dual tumor burden or distant metastasis [4].
One reason for the apparently limited predictive accu-
racy of the traditional staging system is the assumption
that tumor progression is largely a cell-autonomous pro-
cess, focusing only on cancer cells and without properly
considering the host immune response [5]. However, his-
topathological analysis has revealed that tumors are often
infiltrated by a variable degree of inflammatory and lym-
phocytic cells [6]. A closer look reveals that these immune
cells are not distributed randomly, but seem to be orga-
nized in more or less dense infiltrates in the center of the
tumoral zone (CT), at the invasive margin (IM) of tumoral
nests and in lymphoid islets adjacent to the tumor. The
presence of immune cells may reflect a distinct underlying
biology of the tumor, as gene expression profiling and
confirmatory assays have revealed the presence of a broad
signature of inflammation. This signature includes evi-
dence for innate immune activation, chemokines for T cell
recruitment, immune effector molecules, and expression
of immune regulatory factors [7-9].
A new classification of cancer based on the tumor
microenvironment
Recently, multiple articles [8,10-13] and meeting reports
[14-16] were published supporting the hypothesis that
cancer development is influenced by the host immune sys-
tem. This underlines the importance of including systemic
and local immunological biomarkers that should be evalu-
ated even in clinically observable tumors for making deci-
sions regarding patients’ prognosis and prediction to
treatment [5,17]. Numerous data collected from large
cohorts of human cancers demonstrated that the number,
type and location of tumor immune infiltrates in primary
tumors are essential prognostic factor for disease-free and
overall survival. Global analysis of the tumor microenvir-
onment showed that the immune contexture [10], i.e. the
nature, functional orientation, density, and location of
adaptive immune cells within distinct tumor regions influ-
ence the risk of relapse. An immune-classification of
tumors was proposed based on a simple immune score,
quantifying the density and location of immune-cells
within the tumor [11]. This immune-classification has a
prognostic value that may be superior to the AJCC/UICC
TNM-classification, and tumor invasion was shown to be,
in fact, statistically dependent on the host-immune reac-
tion. Indeed, the immune pattern remained the only sig-
nificant criterion over the classical AJCC/UICC TNM
classification for disease free and overall survival, and led
to an editorial entitled “TNM staging in colorectal cancer:
T is for T cell and M is for memory” accompanying the
publication by Mlecnik et al. in the Journal of Clinical
Oncology [11,18].
These results suggest that once human cancer
becomes clinically detectable, the adaptive immune
response plays a role in preventing tumor recurrence.
The ability of effector-memory T cells to recall pre-
viously encountered antigens leads to a protective
response. Following a primary exposure to antigen,
memory T cells disseminate and are maintained for long
periods [19]. The trafficking properties and the long-
lasting antitumor capacity of memory T cells could
result in long-term immunity in human cancer.
Although first described in colorectal cancer, the
impact of the immune cytotoxic and memory T cell
phenotype has been demonstrated in many other
human tumors and appears to be a general phenomenon
[17,20]. It is interesting to note that the value of this
immune phenotype applies not only to various organs of
cancer origin (breast, colon, lung, head and neck, kid-
ney, bladder, ovary, prostate...), but also to various can-
cer cell types (adenocarcinoma, squamous cell
carcinoma, large cell cancer, melanoma, etc).
The Immune Score as a new approach for the
classification of cancer
Considering the probable universal character of the
immune control of tumors, it is essential to begin to
incorporate the immune score as a prognostic factor
[17] and a component of cancer classification [11,13].
This marker has a dual advantage: firstly, it appears to
be the strongest prognostic factor for disease free and
overall survival particularly in early stage cancers, and
secondly, it provides a tool or a target for novel thera-
peutic approaches, including immunotherapy. Current
immunohistochemical technologies allow the application
of such analyses by laboratories concerned with routine
diagnostic and prognostic assessment of tumors.
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conjunction with variable assay protocols across laboratories,
the different immune cell types analyzed, different region
selection criteria, qualitative and semi-quantitative criteria to
measure immune infiltration contribute to the variability of
the results obtained, and raise the concern that specialized
protocols and training may be required. Therefore, it is
essential to pursue assay harmonization to reduce these lim-
itations. Many markers, signatures, and methods have been
described to evaluate the prognosis of cancer patients. Yet,
very few such markers and laboratory assays are used in
clinical practice. Thus, we believe that harmonization of a
assays evaluating the “inflammation”, i.e. the immune score
of the patient is essential. Although there is a need for analy-
tical and clinical validation of the assay before the immune
score for individual patient will reach clinical applicability,
the current immunohistochemical technologies allow the
application and cross-validation of such analysis in labora-
tories performing routine diagnostic and prognostic assess-
ment of tumors. We expect a consensus panel to agree on a
standardized set of assays in order to be able to compare
results in the future, and for developing more effective prog-
nostic and predictive markers to improve clinical decision-
making in the care of cancer patients. Additional markers
could be added subsequently to refine even further the
method. Assay harmonization should minimize data varia-
bility and allow worldwide correlations of immune score
results with clinical outcomes. Harmonization guidelines
resulting from this process are expected to be simple to
implement, and will improve assay performance [21].
A very important clinical translation is the establishment
of an immune score based on the density of two lympho-
cyte populations, cytotoxic and memory T cells (CD8/
CD45RO), both in the center and the invasive margin of
tumors, to establish prognosis of clinical outcome in
patients, even when there is no cancer associated prognos-
tic marker such as in early tumor stage (I/II) patients [13].
In human cancers, a high density of TH1/cytotoxic mem-
ory T lymphocytes located both in the center and the inva-
sive margin of the primary tumor is associated with long
disease free and overall survival and low risk of relapse
and metastasis. This was particularly illustrated in colorec-
tal cancer [4,8,11-13], and should be applicable to most
human tumors [17]. Thus, this immune score classification
may help identify the high-risk patients who would benefit
the most from adjuvant therapy.
An open access call for a broad participation to the
development of a task force dedicated to the evaluation
of the role of Immune Scoring of cancer
Over the past few years, the area of immune regulation at
the level of the tumor microenvironment has gained a
forefront position in cancer research, in melanoma [22]
and all other cancer types. At the same time, advances
have been made in the development of the immunoscore
as a prognostic factor. In an effort to promote the utiliza-
tion of such immunoscore in routine clinical settings
worldwide, the Society for Immunotherapy of Cancer
(SITC), the European Academy of Tumor Immunology
(EATI), the Cancer and Inflammation Program, the
National Cancer Institute, National Institutes of Health,
USA and “La Fondazione Melanoma Onlus” will initiate a
task force on “Immunoscoring as a New Possible
Approach for the Classification of Cancer” that will take
place in Naples, Italy, February 13th, 2012. The working
group is aimed at identifying a strategy for the organiza-
tion of worldwide voluntary participation by various
groups and societies including but not limited to members
of the World Immunotherapy Council that currently
include the Biotherapy Development Association (BDA),
Canadian Cancer Immunotherapy Consortium (CCIC),
Cancer Immunotherapy Consortium (CIC) of the Cancer
Research Institute (CRI), Cancer Immunotherapy Society
(CIMT), the Chinese Society for Clinical Oncology
(CSCO), Committee for Tumor Immunology and Bio-
therapy (TIBT), Dutch Tumor Immunology Working
Party (DTIWP), European Academy of Tumor Immunol-
ogy (EATI), European Society for Cancer Immunology
and Immunotherapy (ESCII), Italian Network for Tumor
Biotherapy (NIBIT), Japanese Association of Cancer
Immunology (JACI), Nordic Center for Development of
Anti-tumour Vaccines (NCV-network), Progress in Vacci-
nation Against Cancer (PIVAC), and the Tumor Vaccine
and Cell Therapy Working Group (TVACT). These
groups share a clinical or basic interest in the immune
biology of the cancer microenvironment and will collabo-
rate to define guidelines to assess the validity of this new
approach. Members of the World Immunotherapy Coun-
cil will meet in February 2012 (subsequently to the task
force meeting in Naples), to discuss participation in this
process and will likely contribute to the discussion by
arranging sessions at their annual meetings through 2012.
Additionally, pathologist associations and other medical
specialty groups will be invited to participate and/or are
welcome to contact the members of the task force to be
included. This editorial, in part, represents an effort to
advertise this project, in an open access forum to obtain
the broadest participation by all interested parties.
Because colorectal cancer has been most comprehen-
sively studied and the prognostic significance of immuno-
logic parameters has been best validated, special emphasis
will be placed in this disease at the beginning. Other can-
cer types, including melanoma, will be discussed as well.
An independent international consensus panel of labora-
tories with expertise in the field immune cell infiltrate eva-
luation in tumors is expectedt od i s c u s sa n da g r e eo na
cross-laboratory assay validation for the development of
an immunoscore prognostic method.
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cept manuscript that will seek broad participation of
potentially interested societies; 2) enhancing the topic of
immune infiltrates as markers for tumor prognosis and/
or response to therapy; 3) stimulate international colla-
borations between research and clinical investigators
focusing on validation studies. The concept manuscript
will seek broad participation of potentially interested
societies. In as much as not all interested parties might
be able to participate in person, an open access manu-
script will facilitate involvement in subsequent efforts of
additional experts who will have missed the first round.
In addition, a two-day workshop on the tumor micro-
environment that will be held October 24-25, 2012 in
Bethesda, MD in conjunction with the Annual Meeting
of the Society for the Immunotherapy of Cancer (SITC)
T h em o s ti m p o r t a n to u t c o me of this activity will be
the development of preliminary guidelines for the colla-
boration between organizations and societies dedicated
to cancer immunotherapy, and/or other aspects of can-
cer biology relevant to its progression and treatment. In
association with and preceding the Annual Meeting of
“la Fondazione Melanoma Onlus”,t h e“First Meeting on
the Immunoscoring as a New Possible Approach in the
Classification of Cancer” will be organized and will be
held in Naples, December 2012.
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